nach oben

Current Breast Cancer Reports

Erschienen in:

27.04.2017 | Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

verfasst von: Johanna Wassermann, Shoshana M. Rosenberg

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Treatment decisions regarding adjuvant endocrine therapy in breast cancer has become increasingly complex, with non-adherence to treatment one of the most crucial issues. We aimed to review the literature on both aspects focusing on new finding regarding assessment, determinants, and interventions of decision-making and adherence to adjuvant endocrine therapy.

Recent Findings

A shared decision-making process is wanted by the patients and can improve patient-related outcomes. Information needs, preferences, and values regarding adjuvant endocrine therapy vary widely. Nearly two-thirds of patients do not take the adjuvant endocrine therapy exactly as prescribed either by not initiating, missing doses, or stopping the treatment early.

Summary

Implementation of tools for a shared decision can be useful in clinical practice, but further development is needed in the field of adjuvant endocrine therapy. Targeted interventions are desirable to improve patients’ adherence to adjuvant endocrine therapy, thereby improving the quality of care and outcomes in breast cancer.

American Cancer Society. Breast cancer facts & figures 2015–2016. Atlanta Am. Cancer Soc. Inc 2015.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69.CrossRefPubMedPubMedCentral

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.CrossRef

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.CrossRefPubMed

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.CrossRefPubMed

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.CrossRefPubMedPubMedCentral

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.CrossRefPubMed

•• Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459–78. This review summarizes the literature published between 1996 and 2012 about adherence to adjuvant endocrine therapy in breast cancer patients in clinical practice. CrossRefPubMedPubMedCentral

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN Guidelines Insights Breast Cancer, version 1.2016. J Natl Compr Cancer Netw. 2015;13:1475–85.CrossRef

10.

Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJH, Liefers G-J, et al. Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014;40:1005–18.CrossRefPubMed

11.

Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol. 2015;22:3809–15.CrossRefPubMedPubMedCentral

12.

Beryl LL, Rendle KAS, Halley MC, Gillespie KA, May SG, Glover J, et al. Mapping the decision-making process for adjuvant endocrine therapy for breast cancer: the role of decisional resolve. Med Decis Mak. 2017;37:79–90.CrossRef

13.

Montori VM, Gafni A, Charles C. A shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetes. Health Expect. Int. J. Public Particip Health Care Health Policy. 2006;9:25–36.

14.

Watt S. Clinical decision-making in the context of chronic illness. Health Expect Int J Public Particip Health Care Health Policy. 2000;3:6–16.

15.

Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA. 1992;267:2221–6.CrossRefPubMed

16.

Crossing the quality chasm: a new health system for the 21st century [Internet]. Available from: http://nationalacademies.org/hmd/Reports/2001/Crossing-the-Quality-Chasm-A-New-Health-System-for-the-21st-Century.aspx

17.

Braddock CH. The emerging importance and relevance of shared decision making to clinical practice. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 2010;30:5S–7S.CrossRef

18.

Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27:1361–7.CrossRefPubMedPubMedCentral

19.

Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns. 2012;86:9–18.CrossRefPubMed

20.

Janz NK, Wren PA, Copeland LA, Lowery JC, Goldfarb SL, Wilkins EG. Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol. 2004;22:3091–8.CrossRefPubMed

21.

Spano J-P, Azria D, Gonçalves A. Patients’ satisfaction in early breast cancer treatment: change in treatment over time and impact of HER2-targeted therapy. Crit Rev Oncol Hematol. 2015;94:270–8.CrossRefPubMed

22.

Brown R, Butow P, Wilson-Genderson M, Bernhard J, Ribi K, Juraskova I. Meeting the decision-making preferences of patients with breast cancer in oncology consultations: Impact on decision-related outcomes. J Clin Oncol. 2012;30:857–62.CrossRefPubMed

23.

Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15:9–19.CrossRefPubMed

24.

Andersen MR, Bowen DJ, Morea J, Stein KD, Baker F. Involvement in decision-making and breast cancer survivor quality of life. Health Psychol. 2009;28:29–37.CrossRefPubMed

25.

• Scholl I, Koelewijn-van Loon M, Sepucha K, Elwyn G, Légaré F, Härter M, et al. Measurement of shared decision making a review of instruments. Z Evidenz Fortbild Qual Im Gesundheitswesen. 2011;105:313–24. A review on existing tools to measure shared decision making. CrossRef

26.

Epstein RM, Street JR RL. Patient-centered communication in cancer care: promoting healing and reducing suffering. US Department of Health and Human Services; 2007.

27.

Farias AJ, Ornelas IJ, Hohl SD, Zeliadt SB, Hansen RN, Li CI, et al. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Support Care Cancer. 2017;25:75–83.CrossRefPubMed

28.

Recio-Saucedo A, Gerty S, Foster C, Eccles D, Cutress RI. Information requirements of young women with breast cancer treated with mastectomy or breast conserving surgery: a systematic review. Breast. 2016;25:1–13.CrossRefPubMed

29.

Kim SI, Lee Y, Son Y, Jun SY, Yun S, Bae HS, et al. Assessment of breast cancer patients’ knowledge and decisional conflict regarding tamoxifen use. J Korean Med Sci. 2015;30:1604–10.CrossRefPubMedPubMedCentral

30.

Feldman-Stewart D, Madarnas Y, Mates M, Tong C, Grunfeld E, Verma S, et al. Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. Breast. 2013;22:919–25.CrossRefPubMed

31.

Nakashima M, Kuroki S, Shinkoda H, Suetsugu Y, Shimada K, Kaku T. Information-seeking experiences and decision-making roles of Japanese women with breast cancer. Fukuoka Igaku Zasshi Hukuoka Acta Medica. 2012;103:120–30.PubMed

32.

Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol. 2005;6:581–8.CrossRefPubMed

33.

Duric VM, Fallowfield LJ, Saunders C, Houghton J, Coates AS, Stockler MR. Patients’ preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? Br J Cancer. 2005;93:1319–23.CrossRefPubMedPubMedCentral

34.

Vaz-Luis I, O’Neill A, Sepucha K, Miller KD, Baker E, Dang CT, et al. Survival benefit needed to undergo chemotherapy: patient and physician preferences. Cancer. 2017;

35.

Légaré F, Stacey D, Turcotte S, Cossi M-J, Kryworuchko J, Graham ID, et al. Interventions for improving the adoption of shared decision making by healthcare professionals. Cochrane Database Syst. Rev. 2014;CD006732.

36.

Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–91.CrossRefPubMed

37.

Belkora JK, Hutton DW, Moore DH, Siminoff LA. Does use of the Adjuvant! model influence use of adjuvant therapy through better risk communication? J Natl Compr Cancer Netw. 2011;9:707–12.CrossRef

38.

Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM. A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology. 2006;15:1001–13.CrossRefPubMed

39.

Vickers AJ, Elkin EB, Peele PB, Dickler M, Siminoff LA. Long-term health outcomes of a decision aid: data from a randomized trial of Adjuvant! In women with localized breast cancer. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 2009;29:461–7.CrossRef

40.

Lipkus IM, Peters E, Kimmick G, Liotcheva V, Marcom P. Breast cancer patients’ treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy. Med Decis Mak Int J Soc Med Decis Mak. 2010;30:464–73.CrossRef

41.

Belkora JK, Volz S, Teng AE, Moore DH, Loth MK, Sepucha KR. Impact of decision aids in a sustained implementation at a breast care center. Patient Educ Couns. 2012;86:195–204.CrossRefPubMed

42.

van der Weijden T, Pieterse AH, Loon MSK, Knaapen L, Légaré F, Boivin A, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf. 2013;22:855–63.CrossRefPubMed

43.

Charles C, Gafni A, Whelan T. Self-reported use of shared decision-making among breast cancer specialists and perceived barriers and facilitators to implementing this approach. Health Expect. 2004;7:338–48.CrossRefPubMedPubMedCentral

44.

Shepherd HL, Tattersall MHN, Butow PN. Physician-identified factors affecting patient participation in reaching treatment decisions. J Clin Oncol. 2008;26:1724–31.CrossRefPubMed

45.

Vogel BA, Bengel J, Helmes AW. Information and decision making: patients’ needs and experiences in the course of breast cancer treatment. Patient Educ Couns. 2008;71:79–85.CrossRefPubMed

46.

Martinez KA, Kurian AW, Hawley ST, Jagsi R. How can we best respect patient autonomy in breast cancer treatment decisions? Breast Cancer Manag. 2015;4:53–64.CrossRefPubMedPubMedCentral

47.

Engelhardt EG, Pieterse AH, van der Hout A, HJCJM d H, Kroep JR, van Quarles Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: a potential barrier to shared decision making. Eur J Cancer. 2016;66:55–66.CrossRefPubMed

48.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34:1134–50.CrossRefPubMedPubMedCentral

49.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: Terminology and definitions. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2008;11:44–7.CrossRef

50.

Hutchins DS, Zeber JE, Roberts CS, Williams AF, Manias E, Peterson AM. Initial medication adherence—review and recommendations for good practices in outcomes research: an ISPOR medication adherence and persistence special interest group report. Value Health. 2015;18:690–9.CrossRefPubMed

51.

Pagani O, Gelber S, Colleoni M, Price KN, Simoncini E. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group trials 13-93 and 14-93. Breast Cancer Res Treat. 2013;142:455–9.CrossRefPubMedPubMedCentral

52.

Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016;34:2452–9.CrossRefPubMed

53.

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.CrossRefPubMed

54.

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108:1515–24.CrossRefPubMedPubMedCentral

55.

Wu J, Lu ZK. Hormone therapy adherence and costs in women with breast cancer. Am J Pharm Benefits. 2013;5:65–70.

56.

McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109:1172–80.CrossRefPubMedPubMedCentral

57.

Rivellese AA, Boemi M, Cavalot F, Costagliola L, De Feo P, Miccoli R, et al. Dietary habits in type II diabetes mellitus: how is adherence to dietary recommendations? Eur J Clin Nutr. 2008;62:660–4.CrossRefPubMed

58.

Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Mahamat A, et al. Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from Pneumocystis jirovecii pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort. PLoS One. 2014;9:e94183.CrossRefPubMedPubMedCentral

59.

Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138:325–8.CrossRefPubMed

60.

Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–62.CrossRefPubMed

61.

Danilak M, Chambers CR. Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2013;19:105–10.CrossRef

62.

Atkinson T, Rodríguez V, Gordon M, Avildsen I, Emanu J, Jewell S, et al. The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review. Oncol Nurs Forum. 2016;43:576–82.CrossRefPubMedPubMedCentral

63.

El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82:268–79.CrossRefPubMed

64.

Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia. Spain Br J Cancer. 2012;107:1249–56.CrossRefPubMed

65.

Oberguggenberger AS, Sztankay M, Beer B, Schubert B, Meraner V, Oberacher H, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer. 2012;12:474.CrossRefPubMedPubMedCentral

66.

Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28:287–300.CrossRefPubMedPubMedCentral

67.

Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.CrossRefPubMed

68.

Moher D, Schulz KF, Altman D. CONSORT Group (consolidated standards of reporting trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–91.CrossRefPubMed

69.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.CrossRefPubMed

70.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.CrossRefPubMed

71.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.CrossRefPubMed

72.

van de Water W, Bastiaannet E, Hille ETM, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist. 2012;17:55–63.CrossRefPubMed

73.

•• Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:354–76. This review summarizes the literature published between 2003 and 2015 about adherence to oral antineoplastic therapies including adjuvant endocrine therapy. CrossRefPubMedPubMedCentral

74.

Sabaté E, Organization WH. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.

75.

Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns. 2014;95:98–103.CrossRefPubMed

76.

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.CrossRefPubMedPubMedCentral

77.

Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107

78.

Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH-Y, et al. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol. 2014;32:2318–27.CrossRefPubMedPubMedCentral

79.

Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–42.CrossRefPubMedPubMedCentral

80.

Brito C, Portela MC, de Vasconcellos MTL. Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014;14:397.CrossRefPubMedPubMedCentral

81.

Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric. 2014;17:252–9.CrossRefPubMed

82.

Bender CM, Gentry AL, Brufsky AM, Casillo FE, Cohen SM, Dailey MM, et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum. 2014;41:274.CrossRefPubMedPubMedCentral

83.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. Eur J Cancer. 2015;51:1890–6.CrossRefPubMed

84.

Fink AK. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor—positive breast cancer. J Clin Oncol. 2004;22:3309–15.CrossRefPubMed

85.

Bright EE, Petrie KJ, Partridge AH, Stanton AL. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat. 2016;158:243–51.CrossRefPubMed

86.

Walker HE, Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol. 2016;5:16–23.CrossRefPubMedPubMedCentral

87.

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133:367–73.CrossRefPubMed

88.

Lee H-S, Lee J-Y, Ah Y-M, Kim H-S, Im S-A, Noh D-Y, et al. Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. Oncology. 2014;86:340–9.CrossRefPubMed

89.

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg J Can Chir. 2014;57:26–32.CrossRef

90.

Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila Pa). 2011;4:1360–5.CrossRef

91.

Rosenberg S, Partridge AH. Drugs don’t work if people don’t take them: non-initiation of endocrine therapy in young women. San Antonio Breast Cancer Symposium; 2016.

92.

Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23:882–90.CrossRefPubMed

93.

Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, et al. COMPliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol. 2014;25:372–7.CrossRefPubMed

94.

Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. Symptoms and symptom attribution among women on endocrine therapy for breast cancer. Oncologist. 2015;20:598–604.CrossRefPubMedPubMedCentral

95.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21:539–46.CrossRefPubMedPubMedCentral

96.

Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer. 2014;120:2403–11.CrossRefPubMedPubMedCentral

97.

Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat. 2014;145:525–34.CrossRefPubMed

98.

Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.CrossRefPubMed

99.

Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast Edinb. Scotl. 2014;23:393–9.CrossRef

100.

Ozakinci G, Sobota A, Humphris G. Fear of cancer recurrence among breast cancer survivors. Curr Breast Cancer Rep. 2014;6:219–25.CrossRef

101.

Heisig SR, Shedden-Mora MC, von Blanckenburg P, Schuricht F, Rief W, Albert U-S, et al. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology. 2015;24:130–7.CrossRefPubMed

102.

Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125:191–200.CrossRefPubMed

103.

Hershman DL, Tsui J, Meyer J, Glied S, Hillyer GC, Wright JD, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J. Natl. Cancer Inst. 2014;106:dju319.

104.

Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J. Natl. Cancer Inst. 2015;107:djv130.

105.

Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 2014;CD000011.

106.

Yu K-D, Zhou Y, Liu G-Y, Li B, He P-Q, Zhang H-W, et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat. 2012;134:307–13.CrossRefPubMed

107.

Hadji P, Blettner M, Harbeck N, Jackisch C, Lück H-J, Windemuth-Kieselbach C, et al. The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24:1505–12.CrossRefPubMed

108.

Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer. 2013;13:407.CrossRefPubMedPubMedCentral

109.

Rosenberg SM, Partridge AH. New insights into nonadherence with adjuvant endocrine therapy among young women with breast cancer. J Natl Cancer Inst. 2015;107

110.

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast Edinb. Scotl. 2015;24:201–7.CrossRef

111.

Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast Edinb Scotl. 2016;26:87–99.CrossRef

112.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35.CrossRefPubMed

Titel: Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer
verfasst von: Johanna Wassermann
Shoshana M. Rosenberg
Publikationsdatum: 27.04.2017
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 2/2017
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-017-0248-5

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Current Trends in Localization Techniques for Non-palpable Breast Lesions: Making the Invisible Visible

Racial/Ethnic Disparities in Breast Cancer Incidence, Risk Factors, Health Care Utilization, and Outcomes in the USA

New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease

Caregiving Stress and Its Toll on Health From a Psychoneuroimmunological Perspective

Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions

Eliminating Surgery in Early-Stage Breast Cancer: Pipe-Dream or Worthy Consideration in Selected Patients?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie